Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study - Concepedia

Concepedia

Publication | Open Access

Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study

DOI Full Paper Access

26

Citations

21

References

2013

Year

Heather‐Jane Au, W. Eiermann, Nicholas J. Robert, Tadeusz Pieńkowski, John Crown, Miguel Martín, Marek Pawlicki, Arlene Chan, John R. Mackey, John A. Glaspy,

Abstract

HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option.

References

	Year	Citations

Page 1